General

Johnson & Johnson Children's Cough Syrup Contaminated In Some Batches - WHO Poised to Issue Global Alert (Updated)
Elon Musk Slips From Richest Person Ranking After Losing Billions In Recent Months: Who's Now Richer?
Patient Data Compromised - UnitedHealth Group Admits Ransom Payment in Cyberattack
Elon Musk Slips From Richest Person Ranking After Losing Billions In Recent Months: Who's Now Richer?
Patient Data Compromised - UnitedHealth Group Admits Ransom Payment in Cyberattack
FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown

General Recent News

UPS Earnings Show The Weight Of $170,000 Salaries While It Learns To Navigate Shipping Slump
UPS delivers mixed Q1 results, with lower revenue and profit due to slower business. Recent salary negotiations also affected finances.
After The 4/20 Smoke Clears: What Do The Billions Spent On Cannabis Say About Sales In Key States?
This year's 4/20 cannabis celebrations demonstrated not only a growth in consumer demand but also the crucial role of technology in understanding this surge. The overall week of 4/20 saw 3x the sales and units sold compared to any typical week.
Cracking the Code: 5 Reasons a Choppy Market Looms
Trendless Markets are an Investor's Worst Nightmare
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow.
Spotify's First Quarter Tells A Story Of Record Profit And An Epic Win
After a year with of layoffs and activist attention that triggered many changes, Spotify Technology S.A. (NYSE: SPOT) managed to surpass both top and bottom estimates.
Fosun International On Cusp Of New 'Asset-Light' Era With Latest Sale
Key Takeaways: Fosun International’s total debt-to-capitalization ratio stood at 50.4% at the end of last year, down 2.9 percentage points from the previous year The company recently announced the sale of most of its stake in Belgian insurer Ageas, and has raised 57.3 billion yuan from similar asset sales over the past two years
Strategies To Use For Tesla Earnings Season: Using Debit Spreads To Capitalize On Earnings Reports
On 4-19-24, Sandra with Trading Made Simple LLC was on Benzinga Live with Zunaid Suleman discussing trade ideas for earnings season. 
General Motors' Potential In EV Transformation Weighed By Analysts After Q1 Beat- Was This a 'Prove Me' Quarter For CEO Mary Barra?
General Motors shares are trading higher on Tuesday after raising its outlook for FY24, following a first-quarter beat. According to Wedbush analyst Daniel Ives, the company is focusing heavily on profitability, with expenses continuing to be a big priority. BofA Securities analyst John Murphy said in a new investor note that there was optimism heading into the quarter.
What Analysts Are Saying About PepsiCo's Q1 Earnings?
PepsiCo Inc's Q1 FY24 success unfolds: a 2.3% sales growth to $18.25 billion surpassing estimates. Adjusted EPS of $1.61 beats consensus, prompting analyst optimism. BofA Securities reiterates a Buy with a $210 price target, citing 5% pricing growth driving gross margin expansion. Meanwhile, Goldman Sachs maintains a Buy with a $200 price target, impressed by topline growth and EPS increase despite challenges from recalls, highlighting PepsiCo's resilience and long-term growth potential.
Elon Musk's Diverse Investments: The Billionaire's Secret Weapon
Exploring Analyst Estimates for Merck Q1 Earnings, Beyond Revenue and EPS
Wall Street analysts forecast that Merck (NYSE: MRK) will report quarterly earnings of $2.01 per share in its upcoming release, pointing to a year-over-year increase of 43.6%. It is anticipated that revenues will amount to $15.34 billion, exhibiting an increase of 5.9% compared to the year-ago quarter.
Biden's Old '0% Inflation' Comment Comes Back To Bite As McKinsey Says New Biggest Splurge For US Consumers Is Groceries
3 Healthcare Mutual Funds To Grab As the Sector Continues to Rebound
Healthcare did not have a great 2023, even as markets turned around from the depths of the year prior. The sector, which roughly accounts for 13% of the S&P 500, lagged last year as investors flocked to massive tech and growth stocks that propelled the markets.
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
Neurocrine Biosciences reports Phase 2 data for NBI-1065845 in major depressive disorder. Results show significant improvement in MADRS scores. William Blair sees the potential for $1 billion+ in sales.

Explore Benzinga's Financial Tools

Find Stocks Tailored to Your Trading Interests
Find Stocks Tailored to Your Trading Interests
Benzinga Pro offers a real-time newsfeed as headlines break on earnings releases, analyst ratings, rumors, the biggest movers, and many more actionable alerts.

Compare Benzinga's Favorite Stock Brokers

Claim Exclusive Offers

Compare Benzinga's Favorite Cryptocurrency Brokers

Claim Exclusive Offers